Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 913-921

  Cunningham, John ^a   Locatelli, Francesco ^b   Rodriguez, Mariano ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b A MANZONI HOSPITAL   (Italy)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM SALT; CINACALCET; DOXERCALCIFEROL; LANTHANUM CARBONATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; TECALCET; VITAMIN D; VITAMIN D DERIVATIVE;

APOPTOSIS; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; LOW DRUG DOSE; MEDICAL LITERATURE; NONHUMAN; PARATHYROID CELL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOGENESIS; PHOSPHORUS RESTRICTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; THERAPY EFFECT; TREATMENT INDICATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CALCIMIMETIC AGENTS; CALCINOSIS; CHRONIC DISEASE; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY DISEASES; PARATHYROID GLANDS; PHOSPHATES; VASCULAR DISEASES;

EID: 79955567444     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06040710     Document Type: Review

References (88)

1. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73: S14-S19, 1999
2. Massry SG: Role of parathyroid hormone in the pathogenesis of the uremic manifestations. Klin Wochenschr 57: 1085-1088, 1979
3. Rodriguez M, Lorenzo V: Parathyroid hormone: A uremic toxin. Semin Dial 22: 363-368, 2009
4. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA: Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphate. Kidney Int 55: 1284-1292, 1999
5. Lewin E, Garfia B, Almaden Y, Rodriguez M, Olgaard K: Au-toregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats. Kidney Int 64: 63-70, 2003
6. Martin KJ, Gonzalez EA, Slatopolsky E: The parathyroids in renal disease: Pathophysiology. In: The Parathyroids: Basic Clinical Concepts, 2nd edition, San Diego, Academic Press Inc., 2001, pp 625-634
7. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15: 2579-2587, 2004
8. Rodriguez M, Nemeth E, Martin D: The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyper-parathyroidism. Am J Physiol Renal Physiol 288: F253-F264, 2005
9. Rodriguez M, Canadillas S, Lopez I, Aguilera-Tejero E, Al-maden Y: Regulation of parathyroid function in chronic renal failure. J Bone Miner Metab 24: 164-168, 2006
10. Mendoza FJ, Lopez I, Canalejo R, Almaden Y, Martin D, Aguilera-Tejero E, Rodriguez M: Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats. Am J Physiol Renal Physiol 296: F605-F613, 2009
11. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007
12. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T: Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77: 211-218, 2010
13. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M: Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77: 232-238, 2010
14. Komaba H, Fukagawa M: FGF23-parathyroid interaction: Implications in chronic kidney disease. Kidney Int 77: 292-298, 2010
15. Lafage-Proust MH: Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int 77: 390-392, 2010
16. Canalejo R, Canalejo A, Manuel Martinez-Moreno J, Encarnacion Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, and Rodriguez M: FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21: 1125-1135, 2010
17. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M: Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67: 1171-1178, 2005
18. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruy-ama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fuka-gawa M: Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67: 1120-1125, 2005
19. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB: Normalization of mineral ion homeo-stasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139: 4391-4396, 1998
20. Drueke T, Martin D, Rodriguez M: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 22: 1828-1839, 2007
21. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K: Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol 13: 2110-2116, 2002
22. Meir T, Levi R, Lieben L, Libutti S, Carmeliet G, Bouillon R, Silver J, Naveh-Many T: Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am J Physiol Renal Physiol 297: F1192-F1198, 2009
23. Rodriguez M, Felsenfeld AJ: PTH, FGF-23 and early CKD. Nephrol Dial Transplant 23: 3391-3393, 2008
24. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M: Postprandial mineral metabolism and secondary hy-perparathyroidism in early CKD. J Am Soc Nephrol 19: 615-623, 2008
25. Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, Kumar R: Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 104: 11085-11090, 2007
26. Canalejo A, Canalejo R, Rodriguez ME, Martinez-Moreno JM, Felsenfeld AJ, Rodríguez M, Almaden Y. Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate. Nephrol Dial Transplant 25: 1087-1097, 2010
27. Tominaga Y, Takagi H: Molecular genetics of hyperparathy-roid disease. Curr Opin Nephrol Hypertens 5: 336-341, 1996
28. Drueke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 11: 1141-1152, 2000
29. Goodman WG, Quarles LD: Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 74: 276-288, 2008
30. Ritter CS, Finch JL, Slatopolsky EA, Brown AJ: Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60: 1737-1744, 2001
31. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73: 300-307, 2008
32. Rodriguez ME, Almaden Y, Canadillas S, Canalejo A, Sien-dones E, Lopez I, Aguilera-Tejero E, Martin D, Rodriguez M: The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 292: F1390-F1395, 2007
33. Garfia B, Canadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, Rodriguez M: Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 13: 2945-2952, 2002
34. Canadillas S, Canalejo R, Rodriguez-Ortiz ME, Martinez-Moreno JM, Estepa JC, Zafra R, Perez J, Munoz-Castaneda JR, Canalejo A, Rodriguez M, Almaden Y: The up-regulation of the parathyroid VDR expression by extracellular calcium is mediated by the ERK1/2-MAPK signaling pathway. Am J Physiol Renal Physiol 298: F1197-1204, 2010
35. Canadillas S, Canalejo A, Santamaria R, Rodriguez ME, Estepa JC, Martin-Malo A, Bravo J, Ramos B, Aguilera-Tejero E, Rodriguez M, Almaden Y: Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol 16: 2190-2197, 2005
36. Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95: 560-567, 2004
37. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19: 213-216, 2008
38. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007
39. Ketteler M: Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 14: 337-342, 2005
40. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxy-lated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 152: 640-648, 2010
41. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1- S201, 2003
42. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
43. Moe SM, Drueke TB: Management of secondary hyperpara-thyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23: 369-379, 2003
44. Brown AJ, Dusso AS, Slatopolsky E: Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 17: 10-19, 2002
45. Walling MW: Intestinal Ca and phosphate transport: Differential responses to vitamin D3 metabolites. Am J Physiol 233: E488-E494, 1977
46. Zittermann A, Schleithoff SS, Koerfer R: Vitamin D and vascular calcification. Curr Opin Lipidol 18: 41-46, 2007
47. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Pari-calcitol versus calcitriol in the treatment of secondary hyper-parathyroidism. Kidney Int 63: 1483-1490, 2003
48. Szabo A, Merke J, Beier E, Mall G, Ritz E: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049-1056, 1989
49. Canalejo A, Almaden Y, Torregrosa V, Gomez-Villamandos JC, Ramos B, Campistol JM, Felsenfeld AJ, Rodriguez M: The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol 11: 1865-1872, 2000
50. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Ki-taoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323: 421-422, 1990
51. Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, Felsenfeld AJ, Casali RA, Caravaca MA, Rodriguez CO: Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 56: 306-317, 1999
52. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH: Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 96: 50-59, 1995
53. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68: 221-228, 1994
54. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, Takagi H: Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroid-ism. World J Surg 20: 744-752, 1996
55. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443, 1993
56. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC: Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288: E125-E132, 2005
57. Simpson RU, Hershey SH, Nibbelink KA: Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103: 521-524, 2007
58. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D: Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74: 170-179, 2008
59. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
60. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among he-modialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
61. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with parical-citol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
62. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andia JB: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74: 1070-1078, 2008
63. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Del-mez J, Arruda J, Lau A, Slatopolsky E: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32: S48-S54, 1998
64. Meric F, Yap P, Bia MJ: Etiology of hypercalcemia in hemodi-alysis patients on calcium carbonate therapy. Am J Kidney Dis 16: 459-464, 1990
65. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701, 1999
66. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D: Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635, 2004
67. Cunningham J, Floege J, London G, Rodriguez M, Shanahan CM: Clinical outcomes in secondary hyperparathyroidism and the role of calcimimetics. NDT Plus 1: i29-i35, 2008
68. Valle C, Rodriguez M, Santamaria R, Almaden Y, Rodriguez ME, Canadillas S, Martin-Malo A, Aljama P: Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 19: 2430-2436, 2008
69. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyper-parathyroidism with the calcimimetic cinacalcet HCl. Neph-rol Dial Transplant 20: 2186-2193, 2005
70. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol 3: 1718-1725, 2008
71. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD: Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5: 110-116, 2010
72. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67: 467-476, 2005
73. Brown EM: Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Neph-rol Hypertens 2: 541-551, 1993
74. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448-453, 1998
75. Galitzer H, Lavi-Moshayoff V, Nechama M, Meir T, Silver J, Naveh-Many T: The calcium-sensing receptor regulates parathyroid hormone gene expression in transfected HEK293 cells. BMC Biol 7: 17, 2009
76. Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, Nishioka M, Hasegawa H, Kurosawa T, Fukagawa M: Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5: 2305-2314, 2010
77. Meola M, Petrucci I, Barsotti G: Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hy-perplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 24: 982-989, 2009
78. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
79. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA: Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23: 2311-2318, 2008
80. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Deh-mel B, Floege J: The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Neph-rol Dial Transplant 2010 [Epub ahead of print]
81. Raggi P, Chertow G, Block G, Urena Torres P, Goodman W, Lopez N, Petavy F, Dehmel B, Floege J: Comparison of cardiovascular calcium scoring methods in the advance study. NDT Plus 3: iii557, 2010
82. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM: Study design and subject baseline characteristics in the ADVANCE Study: Effects of cinacal-cet on vascular calcification in haemodialysis patients. Neph-rol Dial Transplant 25: 1916-1923, 2010
83. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kakuta T, Onoda N, Koiwa F, Yumita S, Kurokawa K: Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant 18 Suppl 3: iii31-iii33, 2003
84. Shiizaki K, Negi S, Hatamura I, Tatsuta K, Shibata M, Shi-mada S, Sakaguchi T, Akizawa T: Direct injection of cal-citriol or its analog into hyperplastic parathyroid glands induces apoptosis of parathyroid cells. Kidney Int Suppl 102: S12-S15, 2006
85. Nakanishi S, Yano S, Nomura R, Tsukamoto T, Shimizu Y, Shin J, Fukagawa M: Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 18: iii47-iii49, 2003
86. Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, Teutonico A, Cazzato F, Basile C: Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol 3: 794-799, 2008
87. Tominaga Y, Matsuoka S, Uno N, Sato T: Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimet-ics. Ther Apher Dial 12[Suppl 1]: S21-S26, 2008
88. Sun Y, Cai H, Bai J, Zhao H, Miao Y: Endoscopic total para-thyroidectomy and partial parathyroid tissue autotransplanta-tion for patients with secondary hyperparathyroidism: A new surgical approach. World J Surg 33: 1674-1679, 2009